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Purpose: The purpose of this study was to analyze thin-section computed
tomography (CT) appearances of interstitial lung diseases before and at the time
of detection of pneumomediastinum, and to evaluate the relationship between
pneumomediastinum and parenchymal changes on thin-section CT.
Materials & methods: We reviewed CT images before and at the time of detection
of pneumomediastinum in 13 patients with idiopathic pulmonary fibrosis (8 patients)
and collagen vascular diseases (5 patient). The extent of the total area of reticular
opacity, increased opacity (ground-glass opacity and consolidation), and honey-
combing were scored, and these scores were compared before and at the time of
detection of pneumomediastinum. We also divided patients into two groups
according to therapy received. Patients in group 1 experienced pneumomediastinum
after or during treatment with corticosteroids or immunosuppressive agents for
acute or subacute exacerbation of interstitial lung disease. Patients in group 2
experienced pneumomediastinum without therapy.
Results: The mean score of all patients for honeycombing significantly increased at
the time of detection of pneumomediastinum (P ¼ 0:003). In group 1, the extent of
increasing opacity had been decreased significantly at the time of detection of
pneumomediastinum (P ¼ 0:028). In group 2, the mean CT score of reticular opacity,Elsevier Ltd. All rights reserved.
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S. Matsuoka et al.12increasing opacity, and honeycombing significantly increased at the time of
detection of pneumomediastinum (P ¼ 0:028, 0.018, and 0.018, respectively).
Conclusions: Spontaneous pneumomediastinum associated with interstitial lung
disease appears to have a tendency to occur under conditions of altered of
parenchymal interstitial lesions.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Spontaneous pneumomediastinum is an uncommon
disorder that is usually benign and self-limiting. A
variety of causes of pneumomediastinum have been
described including mediastinal, pulmonary, chest
wall, and even retroperitoneal pathologies result-
ing from trauma, infection, connective tissue
disorder, assisted ventilation, and trivial routine
life activity such as vigorous coughing, vomiting, or
deep respiratory efforts.1–14 Recently, researchers
have reported that spontaneous pneumomediasti-
num occurred in patients with severe acute
respiratory syndrome (SARS).15,16
Spontaneous pneumomediastinum has been re-
ported to be a rare complication of various types of
interstitial lung disease, including idiopathic inter-
stitial pneumonia1–3 and connective tissue disor-
der.4–8 However, previous series and case reports of
pneumomediastinum associated with interstitial
lung disease focused on precipitating factors,
clinical presentation, and pathogenesis. To our
knowledge, only one report has assessed computed
tomography (CT) findings of lung parenchymal
abnormalities in interstitial lung disease at the
time of detection of pneumomediastinum.2
The mechanism in which the pneumomediasti-
num arises in interstitial lung disease has not
been clarified. The pathophysiology of pneumome-
diastinum was initially described by Macklin and
Macklin17 based on animal experiments. Pneumo-
mediastinum could result from the rupture of
distal pulmonary alveoli due to the rapid increase
in intra-alveolar pressure in the alveoli, allowing
air bubbles to travel along the vascular sheaths
and connective tissue planes to the media-
stinum. Considering this proposed mechanism, we
hypothesized that some changes associated
with the interstitial lung diseases would exist in
the lung parenchyma at the onset of pneumome-
diastinum.
The objective of our study was to analyze serial
changes in CT appearances of interstitial lung
diseases before and at the time of detection of
pneumomediastinum and to evaluate the relation-
ship between pneumomediastinum and changes in
abnormal CT findings in interstitial lung diseases.Materials and methods
Subjects
We retrospectively reviewed the medical records
and CT images of all patients with spontaneous
pneumomediastinum who underwent CT between
May 1999 and March 2004. Nineteen patients had an
interstitial lung disease, including idiopathic inter-
stitial pneumonia and collagen vascular disease.
These indications of CT scan were routine follow-up
of the interstitial lung disease or assessment of
therapeutic effect. Idiopathic interstitial pneumo-
nia included 10 idiopathic pulmonary fibrosis (IPF)
and 2 non-specific interstitial pneumonia (NSIP).
The diagnosis of IPF was based on the recent ATS/
ERS consensus statement on IPF,18 or a clinicoradio-
graphic presentation believed to be highly specific
for IPF.19 Two patient with NSIP was histologically
diagnosed. We excluded 5 patients in whom chest
CT was not done during the previous 6 months to
the time of detection of pneumomediastinum, and
1 patient undergoing mechanical ventilation (2
patients, IPF; 2 patients, NSIP; and 2 patients,
collagen vascular disease). The final study popula-
tion consisted of 13 patients (8 men, 5 women; age
range, 28–91 years; mean age, 66.7718.7 years)
with either IPF (8 patients) or collagen vascular
disease (5 patients; dermatomyositis in 2 patients,
mixed connective tissue disorder in 2 patients, and
rheumatoid arthritis in 1 patient). Our Institutional
Review Board did not require its approval or patient
informed consent for this study.Thin-section CT scanning
Thin-section CT scans were obtained with a variety
of scanners. A total of 26 scans were performed
on the 13 patients before and at the time of
detection of pneumomediastinum. Seven scans in 6
patients were obtained using a multi-detector row
spiral CT scanner (Aquillion or Asteion, Toshiba
Medical, Tokyo, Japan) within one breath hold at
deep inspiration. The scans were obtained with
4 2-mm collimation, with a table feed of
16–18mm per 0.5–0.75 s scanner rotation. Scanning
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512 512 matrix. Raw data were retrospectively
reconstructed with a section thickness of 2-mm
with 10-mm intervals using a lung algorithm.
Nineteen scans in 11 patients were obtained with
a single-detector helical CT scanner. Helical CT
scans (X-Vigor, Toshiba Medical, Tokyo, Japan) were
obtained throughout the entire thorax with 2-mm
collimation with 8–10-mm intervals using a lung
algorithm. Scanning parameters of helical CT were
120 kVp, 180–220mAs, and 1-s scanning time. No
intravenous contrast material was used. The lung
window was set to a width of 1500HU and a window
level 650HU.Evaluation of CT findings
All thin-section CT images were reviewed retro-
spectively by two chest radiologists (Y.K. and S.M.).
The CT scans before and at the time of detection of
pneumomediastinum was evaluated in random
order without knowledge of diagnosis, and the final
assessment was achieved by consensus. CT analysis
included presence and location of reticular opacity,
ground-glass opacity, consolidation, and honey-
combing. Ground-glass opacity was defined as
areas showing a hazy increase of lung attenua-
tion through which vessels could still be seen.
Consolidation was considered present when the
opacities obscured the underlying vessels. Honey-
combing was defined as end-stage lung damage,
which was manifested as multiple thin-wall
cysts.20
The anatomic distribution was noted to be
central if there was a predominance of abnormal-
ities in the inner third of the transverse plane, and
peripheral if there was a predominance of abnorm-
alities in the outer third of the transverse plane. If
abnormalities were seen along the bronchovascular
bundle, the distribution was regarded as peribron-
chial. If the abnormality had no prediction, it was
regarded as random distribution. In the craniocau-
dal direction, zonal predominance was assessed as
upper, or lower. Upper lung zonal predominance
was considered present when most of the abnorm-
alities were above the level of the tracheal carina,
and lower lung zonal predominance was considered
present when most of the abnormalities were
below this level.
Observers then visually scored (to the nearest
5%) the total extent of abnormal parenchyma at
four preselected levels: (a) upper: aortic arch; (b)
middle: carina; (c) lower: between b and d; and (d)
bottom: 1 cm above the dome of the right hemi-
diaphragm. The extent of involvement of eachabnormality was assessed independently for each
of the 4 zones of each lung. The CT scan score was
calculated by multiplying the percentage of
ground-glass opacity, consolidation, and honey-
combing in each zone by a factor that corrected
for differences in volume between the zones. The
ratio of the volumes of the upper, middle, and
lower (lower and bottom) lung zones was estimated
as 1:1.6:1.3, based on previously published data.21
We also assessed the extent of the lung involved
with increasing opacity including ground-glass
opacity and consolidation. CT scan scores were
compared before and at the detection of pneumo-
mediastinum.
We also divided patients into two groups accord-
ing to whether therapy with corticosteroid or
immunosuppressive agents for acute or subacute
exacerbation of interstitial lung disease was given.
Group 1 (n ¼ 6, age: 28–91 years; mean: 61.7
years) consisted of patients in whom pneumome-
diastinum occurred after or during treatment with
corticosteroids or immunosuppressive agents for
acute or subacute exacerbation of interstitial lung
disease. Group 2 (n ¼ 7, age: 66–80 years; mean:
71.0 years) consisted of stable without evidence of
exacerbation of interstitial lung disease who did
not receive corticosteroids or immunosuppressive
agents but who developed pneumomediastinum.
Statistical analysis
All statistical analyses were performed using JMP
5.0.1 software (SAS Institute, Cary, NC). Data are
expressed as mean7standard deviation. Compar-
isons of each CT scan score before and at the
detection of pneumomediastinum were performed
using the Wilcoxon single rank test. For all
statistical analyses, a P-value less than 0.05 was
considered significant.Results
The characteristics and clinical findings of each
patient are shown in Table 1. Two patient had mild
dyspnea, and two patients presented with moder-
ate cough at the time of detection of pneumome-
diastinum. The remaining nine patients had no
respiratory symptom. None of the patients had
been intubated or biopsied close to the time of
detection of pneumomediastinum. The mean ob-
servation period or CT interval between before
and at the detection of pneumomediastinum was
79.6 days (50.5 days in group 1 and, 104.6 days in
group 2).
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Table 1 The patients characteristics and clinical findings.
Patient
number
Sex Age Diagnosis Observation
period
Physical
symptoms
Therapy for
exacerbation
Group 1 with
therapy
1 M 91 IPF 27 Cough,
dyspnea
Steroid pulse
2 F 28 DM 93 Non Steroid,
immunosuppressive
agents
3 F 63 MCTD 13 Non Steroid pulse
4 M 86 IPF 15 Cough Steroid pulse
5 M 73 IPF 95 Non Steroid pulse
6 M 29 MCTD 20 Non Steroid,
immunosuppressive
agents
Group 2 without
therapy
7 M 72 IPF 120 Non —
8 F 66 DM 42 Non —
9 F 80 IPF 160 Non —
10 F 69 IPF 35 Non —
11 M 68 IPF 135 Non —
12 M 74 Rheumatoid
arthritis
98 Non —
13 M 68 IPF 142 Dyspnea —
Note: IPF: idiopathic pulmonary fibrosis, DM: dermatomyositis, MCTD: mixed connective-tissue disease.
Table 2 The abnormal CT findings before and at the detection of pneumomediastinum.
Before pneumomediastinum At detection pneumomediastinum
Cases Extent (%) Cases Extent (%)
Group 1 (n ¼ 6) Reticular opacity 6 (100) 11 6 (100) 9
Ground-glass Opacity 6 (100) 23 6 (100) 10
Consolidation 6 (100) 13 4 (67) 5
Honeycombing 4 (67) 6 4 (67) 9
Group 2 (n ¼ 7) Reticular Opacity 7 (100) 10 7 (100) 15
Ground-glass opacity 5 (71) 8 7 (100) 14
Consolidation 6 (86) 3 7 (100) 7
Honeycombing 6 (86) 11 7 (100) 17
Note: Numbers in parentheses are percentages.
S. Matsuoka et al.14The presence and predominant location of each
CT finding are summarized in Table 2. At the time of
detection of pneumomediastinum, CT scans re-
vealed reticular opacity in 13 patients, ground-
glass opacity in 13 patients, consolidation in 11
patients, and honeycombing in 11 patients. Reti-
cular opacity predominated in the lower lung zone
in 6 patients but was evenly distributed in all zones
of 7 patients, and at the lung periphery in 8
patients. Ground-glass opacity predominated in the
lower lung zone in 8 patients, and at the lung
periphery in 7 patients. Consolidation predomi-
nated in the lower lung zone in 7 patients, and at
the lung periphery in 6 patients. Honeycombingpredominated in the lower lung zone and at the
lung periphery in all patients.
The mean score for all patients for reticular
opacity was 10.174.9 before pneumomediastinum
and 12.176.1 at the time of detection of pneumo-
mediastinum. For all patients, no significant differ-
ences were seen in scores before and at the time of
detection of pneumomediastinum (P ¼ 0:22). In
group 1, no significant difference was found in
scores before and at the time of pneumomediasti-
num (10.573.4 vs. 8.573.4, respectively;
P ¼ 0:17). However, in group 2, the mean score
for reticular opacity was significantly lower before
pneumomediastinum compared with at the time of
ARTICLE IN PRESS
Pneumomediastinum in interstitial lung disease 15detection of pneumomediastinum (9.776.2 vs.
15.276.3, respectively; P ¼ 0:028).
The mean score for all patients for ground-glass
opacity was 14.9712.4 before pneumomediasti-
num and 12.278.7 at the time of detection of
pneumomediastinum. For all patients, no signifi-
cant differences were seen in scores before and at
the time of detection of pneumomediastinum
(P ¼ 0:51). However, when patients were divided
into groups, significant differences were seen
before and at the time of detection of pneumome-
diastinum. In group 1, the mean score for ground-
glass opacity was significantly higher before detec-
tion of pneumomediastinum than at the time of
detection of pneumomediastinum (23.279.8 vs.
10.074.8, respectively; P ¼ 0:028) (Fig. 1). In
contrast, in group 2, the mean score for ground-
glass opacity was significantly lower before pneu-
momediastinum compared with at the time ofFigure 1 Images in 86-year-old man with exacerbation of
idiopathic pulmonary fibrosis. Transverse thin-section CT
shows that ground-glass opacity (white arrowhead) has
been decreased at the detection of pneumomediastinum
(b) as compared with before CT scan (a).detection of pneumomediastinum (7.8710.0 vs.
14.1711.1, respectively; P ¼ 0:018).
The mean consolidation score for all patients was
7.677.9 before pneumomediastinum and 5.974.2
at the time of detection of pneumomediastinum.
For all patients, no significant difference was found
between before and at the time of detection of
pneumomediastinum (P ¼ 0:75). Again, group dif-
ferences were seen. In group 1, the mean score for
consolidation was significantly higher before pneu-
momediastinum than at the time of detection of
pneumomediastinum (12.879.2 vs. 4.574.1, re-
spectively; P ¼ 0:028). In contrast, in group 2, the
mean score for consolidation was significantly
lower before pneumomediastinum than at the time
of detection of pneumomediastinum (3.172.3 vs.
7.174.2, respectively; P ¼ 0:018).
The mean score of all patients for increasing
opacity was 22.4718.1 before pneumomediasti-
num and 18.1711.6 at the time of detection of
pneumomediastinum (p ¼ 0:42). In group 1, The
mean CT score of increasing opacity signifi-
cantly decreased at the time of detection of
pneumomediastinum (35.9715.1 vs 14.577.7,
respectively; P ¼ 0:028) (Fig. 2), and in group 2,
the mean CT score of increasing opacity signifi-
cantly increased at the time of detection of
pneumomediastinum (10.9711.1 vs. 21.2714.0,
respectively; P ¼ 0:018) (Fig. 2).
The mean score of all patients for honeycombing
increased significantly from 8.7710.4 before pneu-
momediastinum to 13.6711.4 at the time of
detection of pneumomediastinum (P ¼ 0:003)
(Fig. 3). When divided into groups, honeycombing
scores before and at the time of detection of
pneumomediastinum were no longer significant in
group 1 (5.977.2 vs. 9.278.5; P ¼ 0:068) (Fig. 4).
However, in group 2, the mean CT score of
honeycombing was significantly increased at
the time of detection of pneumomediastinum
(11.1712.5 before pneumomediastinum vs. 17.37
12.7 at the time of detection of pneumomediasti-
num, P ¼ 0:018) (Fig. 4).Discussion
In this study, we found that the extent of increasing
opacity, including ground-glass opacity and con-
solidation decreased at the detection of pneumo-
mediastinum associated with interstitial lung
disease which had been treated with corticoster-
oids or immunosuppressive agents for exacerbation
of interstitial lung disease. In stable patients
those who had not received treatment with
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Figure 2 Change of CT scores for increased lung opacity
before and at the detection of pneumomediastinum. (a)
In group 1, the extent of increasing opacity had been
decreased significantly at the time of detection of
pneumomediastinum (P ¼ 0:028). (b) In group 2, the
mean CT score of increasing opacity was significantly
increased at the time of detection of pneumomediasti-
num (P ¼ 0:018).
Figure 3 Transverse thin-section CT scans in 72-year-old
man with idiopathic pulmonary fibrosis without therapy.
The extent of honeycombing (white arrowhead) has been
increased at the detection of pneumomediastinum (b) as
compared with before CT scan (a).
S. Matsuoka et al.16corticosteroids or immunosuppressive agents, there
was an increase in the extent of reticular opacity,
increasing opacity, and honeycombing at the
detection of pneumomediastinum. Thus, sponta-
neous pneumomediastinum associated with inter-
stitial lung disease appears to have a tendency to
occur under conditions of altered of parenchymal
lesions. Though we cannot explain the correlation
between the occurrence of pneumomediastinum
and altered parenchymal lesions in interstitial lung
diseases, some speculation is possible.
Spontaneous pneumomediastinum is thought to
begin with a rapid increase in intra-alveolar
pressure, air leaks from the ruptured alveoli and
accumulates along the bronchovascular sheath.17
The basic requirement for alveolar rupture is the
existence of a pressure gradient between the
alveolus and its surrounding structure. The pressure
within the adjacent alveoli is generally assumed to
be equal, so the intra-alveolar wall should remain
intact. However, when intra-alveolar pressure
increases or perivascular interstitial pressure de-
creases, a gradient is created. In our study, the
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Figure 4 Change of CTscores for extent of honeycombing
before and at the detection of pneumomediastinum. (a)
In group 1, no significant difference was found between
before and at the detection of pneumomediastinum
(P ¼ 0:068). (b) In group 2, the difference was significant
(P ¼ 0:018) by Wilcoxon signed rank test.
Pneumomediastinum in interstitial lung disease 17extent of ground-glass opacity and consolidation
was decreased at the detection of pneumomedias-
tinum in patients who had received corticosteroidsor immunosuppresive therapy for exacerbation of
interstitial lung disease. These patients showed
various degrees of improvement following drug
therapy. In patients with deterioration of idiopathic
pulmonary fibrosis, ground-glass opacity has been
shown to correspond pathologically with acute
diffuse alveolar damage or active fibroblastic
foci.22 In these circumstances, alveolar collapse
occurs as a result of structural changes, reduced
compliance, or obliteration of alveoli. Re-expan-
sion of the alveolus as a result of reacting to drug
treatment might increase intra-alveolus pressure.
Thus, pneumomediastinum may occur under such
circumstances in conjunction with the existence of
a damaged alveolar wall. In addition, heteroge-
neous or partial fibrosis might produce an area of
uneven alveolar expansion in which disproportion-
ate alveolar pressure occurs between alveoli. It is
assumed there is an increased risk of rupture in the
hyperinflated alveolus.
In contrast, though the mechanism of action of
corticosteroid therapy for the acute exacerbation
of interstitial pneumonia has not been sufficiently
clarified, Yamanishi et al.23 suggested that the
weakening effects of corticosteroids on the inter-
stitial tissues of the lungs might cause pneumome-
diastinum. In a literature review of 13 cases of
dermatomyositis, pneumomediastinum occurred
during steroid treatment in all but 1 paient.4
Therefore, the relation of pneumomediastinum
generation and steroid therapy must be considered.
Honeycomb cysts usually enlarge slowly over
time.24 In patients with usual interstitial pneumo-
nia, more active inflammation of the pulmonary
interstitium results in faster progression of honey-
combing over long-term follow-up.25 In our patients
without evidence of exacerbation of interstitial
lung disease at the detection of pneumomediasti-
num, the extent of reticular opacity, increasing
opacity, and honeycombing was increased at the
detection of pneumomediastinum. Therefore, it is
possible that active inflammation existed in the
period between before and at the time of pneu-
momediastinum, and that fibrosis may have pro-
gressed asymptomatically. Increases in the air
cystic space as a result of activity of the interstitial
pneumonia and fibrosis may increase the risk for
pneumomediastinum.
The association between pneumomediastinum
and interstitial lung disease has been mentioned
in several articles.1–3 Franquet et al.2 found
spontaneous pneumomediastinum in 4 patients
of 78 patients (5.1%) with idiopathic pulmo-
nary fibrosis. They assessed the presence and
distribution of pulmonary parenchymal abnormal-
ities on CT images at the time of detection of
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S. Matsuoka et al.18pneumomediastinum, and found that parenchymal
abnormalities such as ground-glass attenuation or
honeycombing showed a subpleural predominance.
In a study of 34 patients with interstitial pulmonary
fibrosis, Fujiwara1 identified pneumomediastinum
on chest CT scans in 5 patients (14.7%). However,
they did not assess parenchymal abnormalities at
the onset of pneumomediastinum, and assumed
that honeycombing and violent cough were predis-
posing factors for pneumomediastinum. In our
patients, the mean score for honeycombing sig-
nificantly increased at the time of detection of
pneumomediastinum, however, there was no pa-
tients with prominent clinical symptoms such as
violent cough. O’Connor and Thomas.3 described a
case of pneumomediastinum in a patient with
fibrosing alveolitis. Fibrosing alveolitis produces
area of uneven lung expansion, with hyperinflation
and areas of atelectasis. This author assumed there
was an increased risk of rupture in the hyperin-
flated areas of the lung. However, in these previous
reports, the mechanism in which the pneumome-
diastinum arises in patients with interstitial pneu-
monia was not clarified. On the other hand,
Ichikawa et al.9 reported a case of a patient in
whom pneumomediastinum occurred in association
with hypersensitive pneumonitis, and on lung
biopsy, overdistention or disruption of alveoli with
obliteration of the respiratory bronchioles was
revealed. They speculated that increased intra-
alveolar pressure occurring as a result of check
valve bronchiolar obstruction induced pneumome-
diastinum.
In contrast, Kono et al.4 assessed pneumome-
diastinum in dermatomyosistis associated with
cutaneous vasculopathy in 17 patients; they found
that 14 patients had interstitial pneumonia and 3
did not. Hence, the cause of pneumomediastinum
was assumed to be necrosis of the bronchial wall
due to vasculopathy, and they concluded that
pneumomediastinum is associated not with inter-
stitial pneumonia but with cutaneous vasculopathy.
Santiago et al.6 reported on the occurrence of
pneumomediastinum and interstitial lung disease in
dermatomyosistis without vasculopathy. Cutaneous
vasculopathy was not confirmed in our patients.
Thus, the role of vasculitis as pathogenic mechan-
ism of pneumomediastinum in dermatomyositis has
been controversial.
In one study, a substantial proportion (12%) of
patient with SARS developed spontaneous pneumo-
mediastinum unrelated to the use of positive end-
expiratory pressure ventilation.15 This occurred
most commonly as the ground-glass opacities and
consolidations began to resolve. Autopsies in
patients with SARS showed diffuse alveolar damagein varying phases of organization.26,27 In our
patients who had received steroid therapy, pneu-
momediastinum occurred in a similar fashion. Thus,
the mechanism of developing pneumomediastinum
associated with SARS might arise by the similar
mechanism in interstitial lung disease.
Spontaneous pneumothorax also has been re-
ported to be a rare complication of idiopathic
interstitial pneumonia.28,29 In our study, there was
no case that pneumomediastinum associated with
pneumothorax was seen. Similarly, Franquet et al.2
found spontaneous pneumothorax without pneu-
momediastinum in 5 patients of 78 patients (6.4%)
with IPF. The mechanism of developing pneu-
mothorax may be different from pneumomediasti-
num. Further investigation is required.
The present study has several limitations. First,
there were few pathological diagnoses of inter-
stitial lung disease, because most patients showed
comparatively typical CT findings and clinical
courses of their respective interstitial lung disease,
thus pathological examinations were not required.
Second, there was unequable in the period
between before and at the onset of pneumome-
diastinum. Pneumomediastinum might occur before
the time of detection on CTscan. Third, the present
sample numbers were small for evaluation of
differences among various histological types or
between idiopathic interstitial pneumonia and
collagen vascular disease. Those differences might
affect the results. Fourth, there is the possibility by
except for interstitial pneumonia on cause of
pneumomediastinum. Pneumomediastinum is also
generated by violent cough or pulmonary function
test.30 However, our patients had not suffered from
violent cough, and there was no case of pneumo-
mediastinum generation for a few days after
pulmonary function test.
In conclusion, we found that development of
pneumomediastinum in association with inter-
stitial lung disease is correlated with the alter-
ation of abnormalities in lung parenchyma. Most
patients had no clinical symptom such as violent
cough at the detection of pneumomediastinum,
hence the changes of lung abnormalities pro-
bably causes an increase in intra-alveolar pressure.
When pneumomediastinum occurs in patients re-
ceiving therapy with corticosteroids or immunosup-
pressive agents for acute or subacute exacer-
bation of interstitial lung disease, increasing
opacities, which indicate disease activity, have
been shown to decrease. Conversely, when pneu-
momediastinum occurs in patients who did not
receive corticosteroids or immunosuppressive
agents, the progress of interstitial fibrosis should
be considered.
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